Zacks Small Cap Research – MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00. – Go Health Pro
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Regulatory Update On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company’s mBôs TKA System. The company stated it had completed all supplemental testing and submitted its formal response to the Additional Information … Read more
